IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 330 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,492,344 | +5.1% | 32,900 | -4.9% | 0.02% | +7.1% |
| Q2 2023 | $1,419,638 | +73.5% | 34,600 | +51.1% | 0.01% | +75.0% |
| Q1 2023 | $818,446 | -29.6% | 22,900 | -25.6% | 0.01% | -33.3% |
| Q4 2022 | $1,163,316 | -1.1% | 30,800 | +15.8% | 0.01% | -7.7% |
| Q3 2022 | $1,176,518 | +437.2% | 26,600 | +269.4% | 0.01% | +1200.0% |
| Q4 2021 | $219,000 | -44.1% | 7,200 | -38.5% | 0.00% | -75.0% |
| Q3 2021 | $392,000 | -38.4% | 11,700 | +18.2% | 0.00% | -42.9% |
| Q2 2019 | $636,000 | -49.4% | 9,900 | -36.1% | 0.01% | -53.3% |
| Q1 2019 | $1,258,000 | -0.2% | 15,500 | -33.5% | 0.02% | -11.8% |
| Q4 2018 | $1,260,000 | +12.1% | 23,300 | +6.9% | 0.02% | +30.8% |
| Q3 2018 | $1,124,000 | +23.8% | 21,800 | 0.0% | 0.01% | +18.2% |
| Q2 2018 | $908,000 | -5.5% | 21,800 | 0.0% | 0.01% | -8.3% |
| Q1 2018 | $961,000 | +238.4% | 21,800 | +289.3% | 0.01% | +300.0% |
| Q3 2017 | $284,000 | – | 5,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
| BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
| TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
| DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
| Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
| Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
| ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
| Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
| PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
| Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |